In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Madrigal Pharmaceuticals Inc’s stock clocked out at $327.31, down -2.41% from its previous closing price of $335.39. In other words, the price has decreased by -$2.41 from its previous closing price. On the day, 0.46 million shares were traded. MDGL stock price reached its highest trading level at $344.1747 during the session, while it also had its lowest trading level at $322.91.
Ratios:
To gain a deeper understanding of MDGL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on February 28, 2025, Upgraded its rating to Buy and sets its target price to $422 from $236 previously.
On February 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $400 to $405.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 10 ’25 when Dier Mardi sold 258 shares for $323.04 per share. The transaction valued at 83,344 led to the insider holds 10,440 shares of the business.
FRED CRAVES bought 7,428 shares of MDGL for $2,465,514 on Mar 12 ’25. On Mar 05 ’25, another insider, Waltermire Robert E., who serves as the Senior VP, Chief Pharma Dev. of the company, sold 14,113 shares for $341.32 each. As a result, the insider received 4,817,104 and left with 3,728 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDGL now has a Market Capitalization of 7227070464 and an Enterprise Value of 6598812672. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.12 while its Price-to-Book (P/B) ratio in mrq is 9.55. Its current Enterprise Value per Revenue stands at 36.633 whereas that against EBITDA is -13.283.
Stock Price History:
The Beta on a monthly basis for MDGL is -0.69, which has changed by 0.34380257 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, MDGL has reached a high of $377.46, while it has fallen to a 52-week low of $189.00. The 50-Day Moving Average of the stock is 0.66%, while the 200-Day Moving Average is calculated to be 16.53%.
Shares Statistics:
It appears that MDGL traded 414.77K shares on average per day over the past three months and 478130 shares per day over the past ten days. A total of 22.00M shares are outstanding, with a floating share count of 18.56M. Insiders hold about 15.94% of the company’s shares, while institutions hold 104.01% stake in the company. Shares short for MDGL as of 1740700800 were 3753213 with a Short Ratio of 9.05, compared to 1738281600 on 3982712. Therefore, it implies a Short% of Shares Outstanding of 3753213 and a Short% of Float of 24.270001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
